New peanut allergy drug shows promise in early safety trial
NCT ID NCT06331728
First seen Nov 14, 2025 · Last updated May 16, 2026 · Updated 16 times
Summary
This early-stage study tested a new drug called IGNX001 in 32 adults and older teenagers with peanut allergy. The main goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored for side effects and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fiona Stanley Hospital
Murdoch, Western Australia, 6150, Australia
-
Monash Health, Sleep, Allergy, and Immunology
Clayton, Victoria, 3168, Australia
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
St Vincent's Sydney
Darlinghurst, New South Wales, 2010, Australia
Conditions
Explore the condition pages connected to this study.